SAPIRSTEIN JAMES — SEC Form 4 filings
SEC reporting owner CIK 1559509. 11 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-01-17 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 3,516 shares, $12,172 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 1,887 shares @ $4.96 ($9,360) in Entero Therapeutics, Inc., filed 2024-03-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Entero Therapeutics, Inc. (ENTO) | Chairman and CEO, Director | 4 | — | 4 legs · 3,516 sh · $12,172 | — |
| RENOVARO INC. (RENB) | Director | 2 | — | — | 2 |
| ZyVersa Therapeutics, Inc. (ZVSA) | Director | 2 | — | — | 2 |
| Cocrystal Pharma, Inc. (COCP) | Chief Executive Officer | 1 | — | — | 1 |
| Inmune Bio, Inc. (INMB) | Director | 1 | — | — | 1 |
| Onconetix, Inc. (ONCO) | Director | 1 | — | — | 1 |
Form 4 filings — SAPIRSTEIN JAMES
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Inmune Bio, Inc. (INMB) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 235,000 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | ZyVersa Therapeutics, Inc. (ZVSA) | Grant/award (A): 11,066 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Onconetix, Inc. (ONCO) | Grant/award (A): 3,318 @ $0 | EDGAR |
| 2024-07-18 | 4 | ZyVersa Therapeutics, Inc. (ZVSA) | Grant/award (A): 132 (derivative) @ $0 | EDGAR |
| 2024-07-03 | 4 | Entero Therapeutics, Inc. (ENTO) | Sale (S): 1,289 @ $1.07 | EDGAR |
| 2024-06-27 | 4 | RENOVARO INC. (RENB) | Grant/award (A): 48,137 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | First Wave BioPharma, Inc. (FWBI) | Sale (S): 174 @ $4.23 | EDGAR |
| 2024-03-19 | 4 | RENOVARO INC. (RENB) | Grant/award (A): 28,196 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | First Wave BioPharma, Inc. (FWBI) | Sale (S): 1,887 @ $4.96 | EDGAR |
| 2024-01-17 | 4 | First Wave BioPharma, Inc. (FWBI) | Sale (S): 166 @ $4.20 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1559509 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →